San Diego startup TissueNetix will by the end of this year make two services available for screening human heart cells in order to eliminate toxic compounds during the drug discovery process, according to the company's CEO.

Robert Ellis told BioArray News that TissueNetix is preparing to introduce its Wave technology platform as a service in the second quarter. A second product for cardiotoxicity screening, called the Cardiac Cell Conduction Array, will also be launched as a service later this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.